INDOUS vs SHANTI: Stock Comparison

INDO US BIOTECH vs SHANTI OVERSEAS INDIAUpdated 15 Sept 26, 3:00 PM ISTNSE & company filings

INDO US BIOTECH is the larger company by market capitalisation. INDO US BIOTECH shows a higher ROE, a higher ROCE and a higher net margin, while SHANTI OVERSEAS INDIA shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOUS leads 6; SHANTI leads 3 of 10

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOUSSHANTI

Valuation lens

What price are you paying?

Market CapContext only
₹160 Cr
₹7 Cr
P/E RatioSame reading
0x
P/B RatioSame reading
0x
EPSINDOUS has the higher reading
₹1.51
₹-0.01
Book ValueContext only
₹46.15
₹3.6
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
INDOUS is the larger company
₹160 Cr vs ₹7 Cr
EPS
INDOUS has higher earnings per share
₹1.51 vs ₹-0.01
Revenue Growth (TTM YoY)
SHANTI has faster revenue growth
357.7% vs -22%
EPS Growth (TTM YoY)
SHANTI has faster EPS growth
0% vs -47.3%
Qtr Profit Growth
INDOUS has stronger quarterly profit growth
54.05% vs -137.89%
ROE
INDOUS has a higher ROE
14.18% vs -79.82%
ROCE
INDOUS has a higher ROCE
12.34% vs -22.7%
Net Margin
INDOUS has a higher net margin
11.88% vs -53.83%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOUSSHANTI
SectorFast Moving Consumer GoodsFast Moving Consumer Goods
IndustryOther Agricultural ProductsEdible Oil

Price

MetricINDOUSSHANTI
Live Price₹78.29₹6.15
Day Change0.06%-0.81%
Volume2,09524,478
52-Week High₹159₹12.26
52-Week Low₹70₹4.7
Distance from 52W High-50.76%-49.84%

Valuation

MetricINDOUSSHANTI
Market Cap₹160 Cr₹7 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹1.51₹-0.01
Book Value₹46.15₹3.6
Dividend Yield0%0%

Growth

MetricINDOUSSHANTI
Revenue Growth (TTM YoY)-22%357.7%
EPS Growth (TTM YoY)-47.3%0%
Qtr Sales Growth26.75%
Qtr Profit Growth54.05%-137.89%

Profitability & Leverage

MetricINDOUSSHANTI
ROE14.18%-79.82%
ROCE12.34%-22.7%
Net Margin11.88%-53.83%
Operating Margin14.64%-54.83%
Debt to Equity0.4x0.12x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOUSSHANTI
Promoter Holding68.29%0%
FII Holding0.01% 0.17 pp0%
DII Holding0%
Public Holding31.7% 0.17 pp100%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDO US BIOTECH and SHANTI OVERSEAS INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.